Cencora, Inc. · NYSE:COR
Cencora — AmerisourceBergen — Q2 FY2018 Earnings Presentation
13 slides from Cencora's earnings presentation, May 2, 2018
Slide 1: Q2 FY2018 Financial Results
Q2 FY2018 Financial Results May 2, 2018
Slide 2: Cautionary Note Regarding Forward-Looking Statements
Cautionary Note Regarding Forward-Looking Statements Certain of the statements contained in this presentation are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Words such as “expect,” “likely,” “ou
Slide 3: AmerisourceBergen is creating healthier futures
AmerisourceBergen is creating healthier futures • Shaping healthcare delivery through knowledge, reach and partnership • Providing industry leading services and solutions that improve product access, increase supply chain efficiency and enhance patient care 3
Slide 4: Q2 FY2018 Financial Results: Overview
Q2 FY2018 Financial Results: Overview ▪ AmerisourceBergen is driving execution in an evolving healthcare market - Continued revenue and EPS growth - Anchor customers growing faster than overall market - Strong out-performance in our core pharmaceutical distribution business - Expanding leadership an
Slide 5: Q2 FY2018 Financial Results
Q2 FY2018 Financial Results Adjusted GAAP (Non-GAAP)1 Revenue $41.0B $41.0B % Change (Year-over-Year) 10% 10% Gross Profit $1.3B $1.3B % Change -% 9% Operating Expenses $774M $692M % Change 23% 19% Operating Income $481M $586M % Change (23)% -% Interest Expense, Net $49M $49M % Change 30% 38% Tax Ra
Slide 6: Pharmaceutical Distribution Services Segment
Q2 FY2018 Financial Results: Pharmaceutical Distribution Services Segment Q2 FY2018 Q2 FY2017 Revenue $39.5B $35.7B Operating Income $489M $485M Percentages of Revenue Gross Profit 2.41% 2.42% Operating Expenses 1.17% 1.07% Operating Income 1.24% 1.36% Execution driving continued out-performance i
Slide 7: Other Businesses – Global Commercialization Services & Animal Health
Q2 FY2018 Financial Results: Other Businesses – Global Commercialization Services & Animal Health Q2 FY2018 Q2 FY2017 Revenue $1.6B $1.4B Operating Income $97M $104M Percentages of Revenue Gross Profit 20.48% 21.49% Operating Expenses 14.39% 14.17% Operating Income 6.09% 7.32% World Courier – anot
Slide 8: How AmerisourceBergen Will Drive Value
How AmerisourceBergen Will Drive Value Leverage Scale Enhance Access • Go-to-market strategy • Specialty leadership • Integrated approach • Grow customer share of wallet • Seamless customer • Deepen manufacturer relationships experience • Build across human & animal health Drive Performance & Expand
Slide 9: FY2018 Financial Guidance
FY2018 Financial Guidance1 Expectations on an Adjusted (Non-GAAP) Basis* Revenue Growth 8% to 11% Diluted Earnings Per Share $6.45 to $6.65 Operating Expense Growth** 8% to 10% Operating Income Growth Flat Effective Tax Rate 22% to 23% Free Cash Flow $1.35B to $1.6B Capital Expenditures ~$325M Worki
Slide 10: Appendix
Appendix N) AmerisourceBergen:
Slide 11: Appendix
Appendix Note: For more information related to non-GAAP financial measures, refer to the section titled “Supplemental Information Regarding Non-GAAP Financial Measures” of the Company’s most recent Current Report on Form 8-K furnished under Item 2.02. 11
Slide 12: Appendix
Appendix Note: For more information related to non-GAAP financial measures, refer to the section titled “Supplemental Information Regarding Non-GAAP Financial Measures” of the Company’s most recent Current Report on Form 8-K furnished under Item 2.02. 12
Slide 13: AmerisourceBergen: Where knowledge, reach and partnership shape healthcare delivery
N) AmerisourceBergen*: Where knowledge, reach and partnership shape healthcare delivery.